Verapamil 240 SR Versus Verapamil 120 SR in Arterial Hypertension. A Randomized Double-blind, Placebo-controlled Study with 24-hour Ambulatory Blood Pressure Monitoring

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 1990 Dec 1

PMID 2081142

Authors

L Corea

M Bentivoglio

S BERIOLI

C Bianchini

K Savino

M Sardina

Affiliations

Soon will be listed here.

Abstract

Fifteen patients (6 males, 9 females), age range 36-70 years, were enrolled in a randomized, double-blind, placebo-controlled study according to a Latin-square design, with the aim of comparing 24-hour blood pressure profiles after three 15-day treatment periods with placebo, verapamil SR 120 mg (V120 SR) given twice daily (bid), and verapamil SR 240 mg (V240 SR) given once daily (od). All of the patients were diagnosed as mild or moderate essential hypertensives on the basis of standard casual recordings. Noninvasive 24-hour ambulatory blood pressure (BP) monitoring was performed with an ICR Spacelab 5200 automatic device. In comparison with placebo, a clinically and statistically significant reduction in both systolic and diastolic BP over 24 hours was obtained with both active treatments. Comparison of the two active treatments shows that V240 SR led to a greater reduction in systolic and diastolic BP than V120 SR. No changes in heart rate were observed. Both treatments were well tolerated. In conclusion, both verapamil regimens proved to be effective and safe in treating essential hypertensives, with V240 SR giving better 24-hour BP control.

References

Berglund G, de Faire U, Castenfors J, Andersson G, Hartford M, Liedholm H . Monitoring 24-hour blood pressure in a drug trial. Evaluation of a noninvasive device. Hypertension. 1985; 7(5):688-94. DOI: 10.1161/01.hyp.7.5.688. View

Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A . Antihypertensive and renal effects of orally administered verapamil. Eur J Clin Pharmacol. 1980; 18(5):375-82. DOI: 10.1007/BF00636788. View

Lattuada S, Antivalle M, Rindi M, Montanari M, Alberti D, LIBRETTI A . Slow-release metoprolol and nifedipine in essential hypertension: 24 hour noninvasive ambulatory blood pressure monitoring. J Cardiovasc Pharmacol. 1987; 10 Suppl 10:S99-101. View

Weber M, Cheung D, Graettinger W, Lipson J . Characterization of antihypertensive therapy by whole-day blood pressure monitoring. JAMA. 1988; 259(22):3281-5. View

Frishman W, Charlap S, Michelson E . Calcium channel blockers in systemic hypertension. Am J Cardiol. 1986; 58(1):157-60. DOI: 10.1016/0002-9149(86)90261-4. View

Salmela P, Gordin A, Salo H, Ottoila P, Jounela A . Comparisons of verapamil administration twice and three times daily in hypertension. Ann Clin Res. 1988; 20(3):195-200. View

Leonetti G, Cuspidi C, Sampieri L, Terzoli L, Zanchetti A . Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J Cardiovasc Pharmacol. 1982; 4 Suppl 3:S319-24. View

Vanhees L, Fagard R, Amery A . Effect of verapamil on systemic and brachial artery hemodynamics in normal humans: comparison with effect of atenolol. J Cardiovasc Pharmacol. 1989; 14(4):642-7. DOI: 10.1097/00005344-198910000-00017. View

Novo S, Alaimo G, Abrignani M, Longo B, Muratore G, Strano A . Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. J Cardiovasc Pharmacol. 1989; 13 Suppl 4:S38-41. DOI: 10.1097/00005344-198900134-00010. View

10.

Speders S, Sosna J, Schumacher A, PFENNIGSDORF G . Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol. 1989; 13 Suppl 4:S47-9. DOI: 10.1097/00005344-198900134-00013. View

11.

Gould B, Mann S, Kieso H, Subramanian V, Raftery E . The role of a slow channel inhibitor, verapamil, in the management of hypertension. Acta Med Scand Suppl. 1984; 681:117-23. DOI: 10.1111/j.0954-6820.1984.tb08685.x. View

12.

Figulla H, Kreuzer H, Luig H . [Verapamil, diltiazem or nifedipine in severe left ventricular functional disorder? A comparative study of the immediate hemodynamic effects]. Dtsch Med Wochenschr. 1986; 111(1):11-4. DOI: 10.1055/s-2008-1068391. View

13.

Zanolla L, Padrini R, Piovan D, Olivieri D, Zardini P . Plasma levels of verapamil and its major metabolites during long-term oral treatment, in chronic stable angina. Correlation with the clinical effects of the drug. Cardiologia. 1985; 30(5):369-73. View

14.

Jorgensen N, Walstad R . Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. Pharmacol Toxicol. 1988; 63(2):105-7. DOI: 10.1111/j.1600-0773.1988.tb00919.x. View

15.

Fuenmayor N, Faggin B, Cubeddu L . Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. J Cardiovasc Pharmacol. 1989; 13 Suppl 4:S53-6. DOI: 10.1097/00005344-198900134-00015. View

16.

Lund-Johansen P, Omvik P . Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension. J Cardiovasc Pharmacol. 1987; 10 Suppl 1:S139-48. DOI: 10.1097/00005344-198710001-00026. View

17.

Hansson B, Lyngstam G, Lyngstam O, Ryden L, Thilen U . Antihypertensive effect of felodipine combined with beta-blockade. A comparison between 2 and 3 daily dosages. Drugs. 1985; 29 Suppl 2:131-6. DOI: 10.2165/00003495-198500292-00023. View

18.

Cardillo C, Savi L, MUSUMECI V, Mores N, Mettimano M, Costalunga A . Casual versus 24-hour ambulatory blood pressure recording in the evaluation of chronic administration of sustained-release verapamil. J Hum Hypertens. 1988; 1(4):281-5. View

19.

Spivack C, Ocken S, Frishman W . Calcium antagonists. Clinical use in the treatment of systemic hypertension. Drugs. 1983; 25(2):154-77. DOI: 10.2165/00003495-198325020-00004. View

20.

McCormack P, Latham A, Mee F, Atkins N, OBrien E, OMalley K . The efficacy and duration of action of sustained-release verapamil in essential hypertension. J Cardiovasc Pharmacol. 1989; 13 Suppl 4:S34-7. DOI: 10.1097/00005344-198900134-00009. View